Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naïve patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
Guillermo Lendínez-CanoAna Victoria Ojeda-ClaroEnrique Gómez-GómezPedro Morales JimenezJosé Flores MartinJuan Francisco DominguezJavier AmoresJose Manuel CozarJaime BachillerAlvaro JuárezRamón LinaresEmilio Garcia GalisteoJose Luis Alvarez OssorioMaria José Requena TapiaJuan Moreno JimenezRafael Antonio Medina Lopeznull nullPublished in: The Prostate (2021)
Our study showed a worse performance for the SelectMdx test than previously reported, within a cohort of patients with a PSA 3-10 ng/ml and a normal DRE, with results similar to those from ERSPC + DRE RC and MRI, but with an improvement in the usual PSA pathway. A combination of the Select Mdx test and MRI could improve accuracy, but studies specifically evaluating this scenario with a cost-effective analysis are needed.